J&J’s MonumenTAL-3 Data Rewrites the Myeloma Playbook Before the Ink Dries on DPd
MonumenTAL-3 delivers 81.3% PFS at 24 months for talquetamab plus daratumumab, threatening DPd's grip on earlier RRMM treatment lines.
Multiple Myeloma
MonumenTAL-3 delivers 81.3% PFS at 24 months for talquetamab plus daratumumab, threatening DPd's grip on earlier RRMM treatment lines.